Navigation Links
Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
Date:6/14/2010

Researchers at the Ecole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique already in practice in Europe for the American market. Under the name Cysview, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

Bladder cancer is the fourth most common cancer in men and the eighth most common in women in the US. Being extremely difficult to detect in its early stages, even by the trained eye of a urologist, the importance of increasing its detectability is paramount for the complete removal of the tumors which helps to delay tumor recurrence.

Helping diagnostics and surgical removal

Cysview is instilled in the bladder. After penetrating the bladder wall it is metabolized mainly by the malignant cells, causing them to produce a fluorescent compound. The doctor then examines the bladder with an endoscope camera equipped with a blue light system: the tumors appear as easily-recognizable red spots. The procedure is not only helpful in diagnosing cancer, it is also useful for the surgeon when removing these small tumors, as he can be assured that the tumor is completely removed when no fluorescence remains.

"With Cysview, even a child can recognize these tumors", says Hubert van den Bergh, head of the project at EPFL. Then, he shows several examples where tumors have been forced out of hiding.

American experts have noticed a significant improvement with Cysview, compared to standard white light cystoscopy. A fact that is also supported in Europe with Hexvix, the European name for the product: experts have shown that the rate of recurrence of bladder cancer is significantly lower after treatment.

Application to other types of cancers

"In the future, similar procedures could be used, for instance for colon cancer or other tumors found in the hollow organs", explains Hubert van den Bergh. EPFL's Norwegian partner Photocure, owner of Hexvix/Cysview, is currently involved in developing this domain.

For the moment, this procedure is the only one of its kind approved by the FDA for use in the bladder. "There is no procedure as efficient," insists Georges Wagnires, responsible for the technology transfer in this project at EPFL, "and the market is therefore potentially very large." The approval by the FDA comes after a more than a decade of development work by the scientists at EPFL and their academic partners from the University Hospital Center (CHUV), the University of Lausanne and Photocure.


'/>"/>

Contact: Georges Wagnires
georges.wagnieres@epfl.ch
41-787-423-511
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert  

Related medicine news :

1. Nuvo Research announces early redemption of 5% convertible debentures
2. A better sign of blood vessel narrowing and early coronary artery disease
3. Bad Behavior as a Kid Linked to Early Death in Men
4. Promising new neuroimaging techniques for early detection of Alzheimers disease
5. Symptoms have little value for early detection of ovarian cancer
6. Immune memory formation seen in early stages of viral infection
7. Symptoms Alone Dont Spot Ovarian Cancer Early
8. Early Factors Predict Later-Life Stroke Risk, from the Harvard Health Letter
9. Early menopause can result in earlier onset dementia
10. New Test Might Smell Early Stage Lung Cancer
11. Early EKG Seems to Improve Odds After Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: